As many as seven in 10 people with eczema report that the disease has had a negative impact on their mental health in the past year. About two-thirds of adults with eczema had anxiety scores that were “borderline abnormal” or “abnormal,” and...
Galderma has submitted Biologics License Applications (BLAs) for nemolizumab for the treatment of prurigo nodularis (PN) and for moderate to severe atopic dermatitis (AD) in adolescents and adults. Nemolizumab is a first-in-class investigational monoclonal antibody...
Zelsuvmi™ (berdazimer topical gel, 10.3%) from Ligand Pharmaceuticals, Inc. is now FDA approved for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older. It is the first novel drug approved for the treatment of...
Filsuvez® (birch triterpenes) topical gel from Chiesi Global Rare Diseases has received FDA approval for the treatment of partial thickness wounds in patients 6 months and older with Junctional Epidermolysis Bullosa (JEB) and Dystrophic Epidermolysis Bullosa (DEB)....
Zoryve (roflumilast) topical foam, 0.3% from Arcutis Biotherapeutics has received FDA approval for the treatment of seborrheic dermatitis in individuals 9 years of age and older. Once-daily, steroid-free Zoryve is the first drug approved for seborrheic dermatitis with...
FDA has approved the expanded label for LEO Pharma’s Adbry® (tralokinumab-ldrm) to include pediatric patients aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those...